AU2017301949B2 - Compounds, reagents, and uses thereof - Google Patents
Compounds, reagents, and uses thereof Download PDFInfo
- Publication number
- AU2017301949B2 AU2017301949B2 AU2017301949A AU2017301949A AU2017301949B2 AU 2017301949 B2 AU2017301949 B2 AU 2017301949B2 AU 2017301949 A AU2017301949 A AU 2017301949A AU 2017301949 A AU2017301949 A AU 2017301949A AU 2017301949 B2 AU2017301949 B2 AU 2017301949B2
- Authority
- AU
- Australia
- Prior art keywords
- compound
- subject
- level
- salt
- kidney function
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662367839P | 2016-07-28 | 2016-07-28 | |
| US62/367,839 | 2016-07-28 | ||
| PCT/US2017/044151 WO2018022866A1 (en) | 2016-07-28 | 2017-07-27 | Diagnostic methods, therapeutic agents and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2017301949A1 AU2017301949A1 (en) | 2019-01-31 |
| AU2017301949B2 true AU2017301949B2 (en) | 2021-09-23 |
Family
ID=59579921
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017301949A Active AU2017301949B2 (en) | 2016-07-28 | 2017-07-27 | Compounds, reagents, and uses thereof |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10865183B2 (enExample) |
| EP (1) | EP3491004B1 (enExample) |
| JP (1) | JP6987123B2 (enExample) |
| CN (1) | CN109563127B (enExample) |
| AU (1) | AU2017301949B2 (enExample) |
| CA (1) | CA3032116A1 (enExample) |
| ES (1) | ES2891088T3 (enExample) |
| WO (1) | WO2018022866A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX391220B (es) * | 2013-05-14 | 2025-03-21 | Metabolon Inc | Biomarcadores relacionados a la funcion renal y metodos para usar los mismos. |
| US11182920B2 (en) * | 2018-04-26 | 2021-11-23 | Jerry NAM | Automated determination of muscle mass from images |
| TWI669506B (zh) * | 2018-07-06 | 2019-08-21 | 國軍桃園總醫院 | 計算腎絲球過濾率之方法 |
| CN114829940A (zh) * | 2019-12-16 | 2022-07-29 | 希尔氏宠物营养品公司 | 用于诊断和治疗肾病的方法、试剂盒和组合物 |
| WO2021232211A1 (zh) * | 2020-05-19 | 2021-11-25 | 深圳市中医院 | 诊断肾病的标志物以及诊断方法 |
| CN119355249A (zh) * | 2024-09-20 | 2025-01-24 | 长沙都正生物科技股份有限公司 | 苯乙酰谷氨酰胺及其与氧化三甲胺联用作为糖尿病肾病诊断标志物 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014186311A1 (en) * | 2013-05-14 | 2014-11-20 | Metabolon, Inc. | Biomarkers related to kidney function and methods using the same |
| WO2015087985A1 (ja) * | 2013-12-11 | 2015-06-18 | 株式会社資生堂 | 腎不全の早期診断マーカー |
-
2017
- 2017-07-27 ES ES17751177T patent/ES2891088T3/es active Active
- 2017-07-27 JP JP2019503956A patent/JP6987123B2/ja active Active
- 2017-07-27 US US16/321,135 patent/US10865183B2/en active Active
- 2017-07-27 CA CA3032116A patent/CA3032116A1/en active Pending
- 2017-07-27 CN CN201780046847.5A patent/CN109563127B/zh active Active
- 2017-07-27 EP EP17751177.1A patent/EP3491004B1/en active Active
- 2017-07-27 WO PCT/US2017/044151 patent/WO2018022866A1/en not_active Ceased
- 2017-07-27 AU AU2017301949A patent/AU2017301949B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014186311A1 (en) * | 2013-05-14 | 2014-11-20 | Metabolon, Inc. | Biomarkers related to kidney function and methods using the same |
| WO2015087985A1 (ja) * | 2013-12-11 | 2015-06-18 | 株式会社資生堂 | 腎不全の早期診断マーカー |
Non-Patent Citations (3)
| Title |
|---|
| ROBERT G. FASSETT ET AL, "Biomarkers in chronic kidney disease: a review", KIDNEY INTERNATIONAL, (2011-10-01), vol. 80, no. 8, pages 806 - 821 * |
| SABINE GEBAUER ET AL, "Three-Dimensional Quantitative Structure-Activity Relationship Analyses of Peptide Substrates of the Mammalian H + /Peptide Cotransporter PEPT1", J. Med Chem, (2003-12-01), vol. 46, no. 26, pages 5725 - 5734 * |
| W L Mock ET AL, "Specificity and pH dependence for acylproline cleavage by prolidase", Journal of Biological Chemistry, (1990-11-15), pages 19600 - 19605 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019531261A (ja) | 2019-10-31 |
| CA3032116A1 (en) | 2018-02-01 |
| JP6987123B2 (ja) | 2021-12-22 |
| WO2018022866A1 (en) | 2018-02-01 |
| CN109563127A (zh) | 2019-04-02 |
| EP3491004B1 (en) | 2021-09-01 |
| ES2891088T3 (es) | 2022-01-26 |
| US10865183B2 (en) | 2020-12-15 |
| AU2017301949A1 (en) | 2019-01-31 |
| US20190152907A1 (en) | 2019-05-23 |
| EP3491004A1 (en) | 2019-06-05 |
| CN109563127B (zh) | 2024-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017301949B2 (en) | Compounds, reagents, and uses thereof | |
| US20210116467A1 (en) | Diabetes-related biomarkers and treatment of diabetes-related conditions | |
| US12055535B2 (en) | Trimethylamine compounds as risk predictors of cardiovascular disease | |
| JP2022091763A (ja) | 肝疾患関連バイオマーカーおよびその使用方法 | |
| CA2775033C (en) | Method for the diagnosis of non-alcoholic steatohepatitis based on a metabolomic profile | |
| US20200110069A1 (en) | Diagnostic methods, therapeutic agents and uses thereof | |
| US20230091848A1 (en) | Disease detection and treatment based on phenylacetyl glutamine levels | |
| US11680042B2 (en) | Compounds, reagents, and uses thereof | |
| WO2019097089A1 (en) | Methods for prediction and early detection of diabetes | |
| WO2012007531A2 (en) | Methods and compositions for diagnosing medical conditions | |
| US20160195550A1 (en) | Metabolism of sod1 in csf | |
| JP7169594B2 (ja) | 糖尿病合併症用マーカー |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ COMPOUNDS, REAGENTS, AND USES THEREOF |
|
| FGA | Letters patent sealed or granted (standard patent) |